Stocktoria
Inogen Inc INGN
Inogen Inc (INGN) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $348.7M at a -6.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.35 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.451 |
| Retained earnings / assets | -0.588 |
| EBIT / assets | -0.101 |
| Equity / liabilities | 1.807 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| INGN | Inogen Inc | 4/9 | 2.26 | — | +3.9% |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC. | 4/9 | -2.1 | — | +27.1% |
| LAKE | LAKELAND INDUSTRIES INC | 2/9 | 4.56 | — | +15.2% |
| SMTI | Sanara MedTech Inc. | 4/9 | -1.26 | — | +19% |
| CDRE | Cadre Holdings, Inc. | 6/9 | 3.7 | 27.2 | +7.5% |
| APT | ALPHA PRO TECH LTD | 4/9 | 12.4 | 16.1 | +2.3% |
| MYO | MYOMO, INC. | 3/9 | -8.82 | — | +25.7% |
About Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.
FAQ
Is INGN financially healthy?
Inogen Inc's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does INGN pay a dividend?
No, Inogen Inc does not currently pay a dividend.
How profitable is INGN?
In FY2025, Inogen Inc had a net margin of -6.5% and a return on equity of -11.8%.
Is INGN overvalued or undervalued?
Inogen Inc trades at about 6.2× trailing earnings — below its 10-year norm (10-year range 47.1×–126.9×, median 66.4×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for INGN?
The average Wall-Street price target for Inogen Inc is $12.67, about 118.0% above the recent price, from 3 analysts.
Is INGN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Inogen Inc: a Piotroski F-score of 4/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.